HIND News & Events

Vyome Holdings announced the signing of an agreement with Impetis Biosciences, a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor. "We are building Vyome with focus and discipline in one of the most attractive segments in biotech, the immuno-inflammatory market, expected to exceed $430 billion by 2034, with the JAK inhibitor segment alone representing a significant ~$57 billion opportunity," said Venkat Nelabhotla, CEO of Vyome. "This transaction highlights the strength of the US-India innovation corridor in sourcing high-quality assets efficiently. The transaction is structured to be very capital-efficient, with consideration tied to commercialization. Any future development will be driven through non-dilutive pathways, allowing us to remain fully focused on executing our core strategy around VT-1953."

Vyome Holdings presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for symptoms of Malignant Fungating Wounds, MFW, at the 2026 American Association for Cancer Research, AACR, Annual Meeting in San Diego, on April 21, 2026. Key highlights: VT-1953 topical gel significantly reduced MFW-associated severe malodor over a 14 Day period as scored by investigators. VT-1953 efficacy was significantly superior to the vehicle control; 70% of patients treated with VT-1953 vs 0% of patients treated with vehicle reported an improvement in patient-reported outcome measure of impact of malodor on life by Day 14; Patients treated with VT-1953 reported a clinically significant 2 point improvement in lesion pain by Day 14 as scored using a 10-point VAS scale. No change seen in vehicle-treated arm.